• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A gene silencing-based approach to tackle fatty liver disease.

作者信息

Strnad Pavel, Schrader Christina, Brunetti-Pierri Nicola

机构信息

Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.

Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Naples, Italy.

出版信息

Mol Ther Methods Clin Dev. 2024 Feb 9;32(1):101198. doi: 10.1016/j.omtm.2024.101198. eCollection 2024 Mar 14.

DOI:10.1016/j.omtm.2024.101198
PMID:38371609
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10869297/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5a/10869297/e10145e4b510/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5a/10869297/e10145e4b510/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae5a/10869297/e10145e4b510/gr1.jpg

相似文献

1
A gene silencing-based approach to tackle fatty liver disease.一种基于基因沉默的方法来应对脂肪肝疾病。
Mol Ther Methods Clin Dev. 2024 Feb 9;32(1):101198. doi: 10.1016/j.omtm.2024.101198. eCollection 2024 Mar 14.
2
Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia.体内肝脏脂肪酸转运蛋白5的沉默可逆转饮食诱导的非酒精性脂肪性肝病并改善高血糖。
J Biol Chem. 2008 Aug 8;283(32):22186-92. doi: 10.1074/jbc.M803510200. Epub 2008 Jun 3.
3
Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease.应对非酒精性脂肪性肝病的药物基因组学和个性化方法。
Pharmacogenomics. 2016 Jul;17(11):1273-1288. doi: 10.2217/pgs-2016-0047. Epub 2016 Jul 5.
4
Understanding gut-liver axis nitrogen metabolism in Fatty Liver Disease.了解脂肪性肝病中的肠-肝轴氮代谢。
Front Endocrinol (Lausanne). 2022 Dec 15;13:1058101. doi: 10.3389/fendo.2022.1058101. eCollection 2022.
5
Prevention and treatment of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的防治。
Dig Liver Dis. 2010 May;42(5):331-40. doi: 10.1016/j.dld.2010.02.004. Epub 2010 Mar 6.
6
Loss and gain of function of Grp75 or mitofusin 2 distinctly alter cholesterol metabolism, but all promote triglyceride accumulation in hepatocytes.Grp75 或线粒体融合蛋白 2 的功能丧失或获得，均可明显改变胆固醇代谢，但均促进肝细胞内甘油三酯的蓄积。
Biochim Biophys Acta Mol Cell Biol Lipids. 2021 Dec;1866(12):159030. doi: 10.1016/j.bbalip.2021.159030. Epub 2021 Aug 20.
7
A novel tasi RNA-based micro RNA-induced gene silencing strategy to tackle multiple pests and pathogens in cotton (Gossypium hirsutum L.).基于新型 tasi RNA 的 micro RNA 诱导基因沉默策略，用于防治棉花（Gossypium hirsutum L.）中的多种病虫害。
Planta. 2022 Dec 20;257(1):20. doi: 10.1007/s00425-022-04055-2.
8
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis.Neddylation 抑制通过 DEPTOR-mTOR 轴促进肝脏脂肪酸氧化改善非酒精性脂肪性肝病中的脂肪变性。
Mol Metab. 2021 Nov;53:101275. doi: 10.1016/j.molmet.2021.101275. Epub 2021 Jun 18.
9
Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease.沉默脂肪酸结合蛋白1可改善非酒精性脂肪性肝病小鼠的肝脂肪变性、炎症和氧化应激。
FEBS Open Bio. 2017 Jun 5;7(7):1009-1016. doi: 10.1002/2211-5463.12240. eCollection 2017 Jul.
10
Influences of sterol regulatory element binding protein-1c silencing on glucose production in HepG2 cells treated with free fatty acid.固醇调节元件结合蛋白-1c 沉默对游离脂肪酸处理的 HepG2 细胞葡萄糖生成的影响。
Lipids Health Dis. 2019 Apr 6;18(1):89. doi: 10.1186/s12944-019-1026-3.

本文引用的文献

1
Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers.肝细胞靶向性siTAZ疗法可降低采用NASH饮食喂养的具有人源化肝脏的嵌合小鼠的肝纤维化程度。
Mol Ther Methods Clin Dev. 2023 Nov 23;31:101165. doi: 10.1016/j.omtm.2023.101165. eCollection 2023 Dec 14.
2
Modern therapeutic approaches to liver-related disorders.现代肝脏相关疾病治疗方法。
J Hepatol. 2022 Jun;76(6):1392-1409. doi: 10.1016/j.jhep.2021.12.015.
3
Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
鉴定和优化针对 PNPLA3 I148M 的小等位基因特异性 siRNA 以预防非酒精性脂肪性肝病。
Nucleic Acid Ther. 2021 Oct;31(5):324-340. doi: 10.1089/nat.2021.0026. Epub 2021 Jul 23.
4
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.治疗非酒精性脂肪性肝病和 2 型糖尿病的新兴治疗方法。
Nat Rev Endocrinol. 2021 Aug;17(8):484-495. doi: 10.1038/s41574-021-00507-z. Epub 2021 Jun 15.
5
Mechanisms and disease consequences of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的机制及疾病后果
Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015.
6
Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation.沉默肝 MCJ 通过增加线粒体脂肪酸氧化来减轻非酒精性脂肪性肝病 (NAFLD)。
Nat Commun. 2020 Jul 3;11(1):3360. doi: 10.1038/s41467-020-16991-2.
7
Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.比较非酒精性脂肪性肝病小鼠模型和患者肝组织的基因表达谱。
Gastroenterology. 2016 Sep;151(3):513-525.e0. doi: 10.1053/j.gastro.2016.05.051. Epub 2016 Jun 16.
8
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis.Pnpla3I148M基因敲入小鼠在脂滴上积累PNPLA3并发展为肝脂肪变性。
Hepatology. 2015 Jan;61(1):108-18. doi: 10.1002/hep.27242. Epub 2014 Oct 1.
9
Mice with human livers.带有人类肝脏的老鼠。
Gastroenterology. 2013 Dec;145(6):1209-14. doi: 10.1053/j.gastro.2013.09.009. Epub 2013 Sep 13.
10
The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals.Scap/SREBP 通路对于动物的糖尿病性脂肪肝和碳水化合物诱导的高甘油三酯血症的发展是必不可少的。
Cell Metab. 2012 Feb 8;15(2):240-6. doi: 10.1016/j.cmet.2011.12.017.